Icatibant Ethypharm

Icatibant, the active ingredient in Icatibant Ethypharm, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL solution for injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid symptom relief by targeting the underlying bradykinin pathway.

GNH USA supplies Icatibant Ethypharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across multiple markets.

Icatibant is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity. - Acute hereditary angioedema attacks (C1‑inhibitor deficiency): rapid reduction of swelling and pain. - Hereditary angioedema type I: alleviates symptoms during an attack. - Hereditary angioedema type II: controls bradykinin‑mediated edema during episodes.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin irritation. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema paradox: rare worsening of swelling. - Infection at injection site: signs of cellulitis or abscess. - Thrombocytopenia: low platelet count observed in isolated cases. - Cardiovascular events: rare myocardial ischemia.

Before using Icatibant, consider the following precautions: - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown excretion; evaluate potential effects on infant. - Renal impairment: monitor as clearance may be reduced. - Concomitant ACE inhibitors: increased risk of angioedema; observe closely. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines as follows: Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may increase angioedema risk. - Angiotensin receptor blockers (ARBs): potential for enhanced bradykinin‑mediated swelling. Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may exacerbate hereditary angioedema. - NSAIDs: can worsen swelling or pain during attacks. - Diuretics: monitor blood pressure and fluid balance.